このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

限局性前立腺癌の治療のためのマイクロ波針サーモアブレーション

2026年11月4日 更新者:CHIU Ka Fung Peter、Chinese University of Hong Kong

MRI-超音波融合臓器追跡のガイダンスの下での限局性前立腺癌の治療のためのマイクロ波針熱切除:第2相試験。

Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the surrounding organs like rectum and bladder. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the target lesion without treating other benign areas, resulting in disease cure in majority of cases with less treatment morbidity. Microwave treatment to the prostate has been performed since more than 20 years ago for benign prostatic hyperplasia and is approved by FDA in United States. It exerts its effect through thermal destruction of prostate tissue. Targeted treatment of localized prostate cancer using microwave needle ablation guided by MRI and Ultrasound imaging has been performed recently and was shown to be safe and effective. Our study aims to assess the effectiveness of this focal therapy in treating localized prostate cancer.

調査の概要

詳細な説明

Prostate cancer screening with Prostate specific antigen (PSA) has resulted in an increase in the diagnosis of localized prostate cancer. The traditional approach for treating low-risk and intermediate-risk prostate cancer includes definitive treatment with either radical prostatectomy or radiotherapy, both of which are associated with considerable morbidity mainly in the area of genitourinary and bowel complications. Active surveillance is one of the options for early low grade prostate cancers, but about half of these men would convert to radical treatment in 10 years' time. In the case of localized intermediate risk prostate cancer, active surveillance is not a good option as it is associated with inferior oncological outcomes in subsequent radical treatment

Focal therapy for localized prostate cancer is the middle ground between active surveillance and radical treatment like prostatectomy or radiotherapy. Instead of monitoring a tumor to see when it is going to progress, focal therapy ablates the target lesion with the aim to reduce or avoid radical treatment. Although the efficacy of focal therapy appeared to be inferior to radical treatment with higher recurrence rates of 20-50%, repeated focal treatment is feasible and the complication profile of focal therapy was significantly better. A recent publication showed that in men with majority intermediate risk prostate cancer, 5 and 8-year freedom from radical treatment was 91% and 81%. This avoids the majority of patients with localized prostate cancer from receiving a radical treatment with potential complications. A recent consensus panel agreed that focal therapy should be defined as ablation of the dominant or index lesion only .

Numerous energy modalities have been utilized for focal therapy of prostate cancers, including High-intensity focused ultrasound (HIFU), Cryotherapy, Photodynamic therapy (PDT), Focal laser ablation (FLA), irreversible electroporation (IRE), and focal brachytherapy. All of them are still being considered experimental according to the latest international guideline due to inferior oncological outcomes (high recurrence and retreatment rates) and lack of long term data. The targeting mechanisms during focal therapies are largely cognitive after the operator read the MRI, resulting in limited precision and possible over or under-treatment. Under-treatment would result in residual disease and treatment failure, while over-treatment might result in complications similar to that in radical treatment. The limitation of MRI in revealing all significant tumors in the prostate and the inability to treat MRI-invisible tumors using existing focal therapy platforms also contributed to treatment failure. However, there is still a significant amount of focal therapies being performed worldwide due to its lower overall morbidity than radical treatment, feasibility of repeated focal treatment, and feasibility to proceed to radical treatment in treatment-failure cases.

Microwave treatment to prostate, Transurethral microwave therapy (TUMT), has been performed since more than 20 years ago for benign prostatic hyperplasia as an office procedure under local anaesthesia. It has not been used in prostate cancer treatment until recently a group in France conducted a single arm pilot study using organ-based tracking (OBT) MRI-Ultrasound fusion-guided microwave therapy using Koelis system for focal treatment of prostate cancer. (Clinical Trials number: NCT03023345) The treatment was done in 10 patients using microwave needles via transrectal route under general anaesthesia, with the primary outcome of complete necrosis of the index tumour on prostate MRI on day 7. The results were being reported in a conference paper, showing 80% (8/10) cases with complete necrosis of index tumor on day-7 MRI, and 20% (1/5) targeted biopsy of tumor showing residual low grade cancer at 6 months. No adverse event or complication occurred in all 10 cases.

MRI-Ultrasound fusion-guided prostate needle biopsy has been performed transperineally in Prince of Wales Hospital under routine basis. In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach under general anaesthesia. Most focal therapy modalities treat lesion that can be seen on MRI and confirmed on biopsy. In cases where significant cancer was located only on systematic biopsy but not on MRI, half or whole gland treatment is usually needed. In the microwave needle ablation guided by organ-based tracking (OBT) MRI-Ultrasound fusion using Koelis system, the positive systematic cores that is not visible on MRI can be accurately localized at the time of biopsy using Koelis system and treated subsequently.

研究の種類

介入

入学 (実際)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Hong Kong、香港
        • Prince of Wales Hospital, Chinese University of Hong Kong

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

45年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

Inclusion Criteria:

  • Men aged between 45 - 75 years
  • Life expectancy > 10 years upon recruitment
  • Localized low or intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy
  • Organ-confined prostate cancer on MRI
  • PSA < 20 ng/mL
  • At least 1 MRI visible lesion present and size ≤15mm, and Targeted biopsy showing Gleason score 6 (with cancer core length ≥6mm) or Gleason score 7 (3+4 or 4+3), With or without positive Systematic biopsy (out of 24 systematic cores) away from MRI visible target showing Gleason 6 cancer

Exclusion Criteria:

  • Patients unfit for MRI exam or MR gadolinium contrast
  • Patients with previous treatment of prostate cancer
  • Patients with maximal length of target lesion >15mm
  • Patients with MRI-visible or invisible lesion within 10mm from rectum or 10mm from sphincter on MRI
  • Patients with >3 areas (MRI-visible or invisible) of prostate cancer
  • Patients with Gleason score 4+4 or any Gleason pattern 5 cancer
  • Patients with bladder pathology including bladder stone and bladder cancer
  • Patients with urethral stricture
  • Patients with neurogenic bladder and/or sphincter abnormalities

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Microwave needle thermoablation of prostate cancer

The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.

In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The oncological control of prostate cancer
時間枠:At 6 months after treatment

Any cancer detected on biopsy of each ablated area

At 6 months after treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Per-patient analysis of any cancer detected on biopsy of any ablated areas
時間枠:At 6 months after treatment

Per-patient analysis of any cancer detected on biopsy of any ablated areas

At 6 months after treatment
Cancer detection on biopsy of each ablated MRI visible lesion
時間枠:At 6 months after treatment

Cancer detection on biopsy of each ablated MRI visible lesion

At 6 months after treatment
Cancer detection on biopsy of each ablated MRI invisible lesion
時間枠:At 6 months after treatment

Cancer detection on biopsy of each ablated MRI invisible lesion

At 6 months after treatment
Gleason 4 or 5 cancer detected on biopsy of ablated area
時間枠:At 6 months after treatment

Gleason 4 or 5 cancer detected on biopsy of ablated area

At 6 months after treatment
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy
時間枠:At 6 months after treatment

Out-of-field recurrence: Any cancer outside treated area on systematic biopsy

At 6 months after treatment
Common Terminology Criteria for Adverse Events (CTCAE) v5.0
時間枠:1 year

Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0

1 year
Dimension of necrosis area on MRI
時間枠:At 1 week

Dimension of necrosis area on MRI

At 1 week
PSA change
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

PSA change after treatment

At baseline, 4 weeks, 3 months, 6 months and 12 months
International Prostate Symptom Score (IPSS) score
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

Urinary symptoms measured by IPSS score, score ranging from 0-35 (the higher the worse)

At baseline, 4 weeks, 3 months, 6 months and 12 months
Sexual side effects, up to 1 year, measured by International Index of Erectile Function 5-item version (IIEF-5) score
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

Sexual side effects, up to 1 year, measured by IIEF-5 score (ranging from 1-25), the lower the worse

At baseline, 4 weeks, 3 months, 6 months and 12 months
Expanded Prostate cancer Index Composite (EPIC-26) questionnaire
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

Quality of life in patients with prostate cancer measured by EPIC-26, range 0-100, the higher score the better the quality of life

At baseline, 4 weeks, 3 months, 6 months and 12 months
Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

Rectal side effects measured by CTCAE rectal toxicity, Grade 1-5 for any rectal toxicity, the higher the score the more severe the toxicity

At baseline, 4 weeks, 3 months, 6 months and 12 months
EQ-5D (EuroQol 5 dimensions) questionnaire
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

Quality of life measured by ED-5Q questionnaire, with 5 components [Mobility, Self Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression)], and a Visual analogue scale (EQ-VAS) score, the higher the score the better in quality of life

At baseline, 4 weeks, 3 months, 6 months and 12 months
QLQ-C30 (Quality of life Core 30) questionnaire
時間枠:At baseline, 4 weeks, 3 months, 6 months and 12 months

Quality of life measured by QLQ-C30, score 0-100, the higher the score the better in quality of life

At baseline, 4 weeks, 3 months, 6 months and 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Peter KF Chiu, MBChB,FRCSEd、Chinese University of Hong Kong

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年10月8日

一次修了 (実際)

2023年2月16日

研究の完了 (実際)

2023年4月11日

試験登録日

最初に提出

2019年10月1日

QC基準を満たした最初の提出物

2019年10月1日

最初の投稿 (実際)

2019年10月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2025年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する